p95HER2 expression in HER2-positive breast cancer with primary resistance

被引:0
作者
Goh, Chih Wan [1 ,2 ,3 ]
Yang, Benlong [1 ,2 ]
Chi, Yayun [1 ,2 ]
Wu, Jiong [1 ,2 ,4 ]
机构
[1] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Dept Breast Surg, Shanghai Canc Ctr Xiamen, Xiamen, Fujian, Peoples R China
[4] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai 200032, Peoples R China
来源
PRECISION MEDICAL SCIENCES | 2024年 / 13卷 / 02期
基金
中国国家自然科学基金;
关键词
breast cancer; molecular targeted therapy; trastuzumab; CARBOXY-TERMINAL FRAGMENT; HER2; RECEPTOR; TRASTUZUMAB; LAPATINIB; PROTEIN; BENEFIT; GROWTH;
D O I
10.1002/prm2.12128
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
p95HER2 isoform is a truncated form of HER2 that retains the C terminal domain but lacks an N terminal trastuzumab binding site. From 2014 to 2016, we assessed the expression of p95HER2 expression in 59 HER2-positive breast cancer patients from FUSCC. The median follow-up was 54 months. In our study, 19 patients (32.2%) were p95HER2 positive. p95HER2-positive expression rate is higher in premenopausal patients than in postmenopausal patients (68.4% vs. 31.6%, P = .026). p95HER2 positive was found more in premenopausal patients and was associated with worse DFS (hazard ratio, 2.21; 95% CI, 1.06-4.61; P = .034), indicating that p95HER2 expression tends to be a more aggressive isoform type of HER2-positive breast cancer.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 27 条
[1]   Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 [J].
Abraham, Jame ;
Montero, Albert J. ;
Jankowitz, Rachel C. ;
Salkeni, Mohamad Adham ;
Beumer, Jan H. ;
Kiesel, Brian F. ;
Piette, Fanny ;
Adamson, Laura M. ;
Nagy, Rebecca J. ;
Lanman, Richard B. ;
Sperinde, Jeff ;
Huang, Weidong ;
Allegra, Carmen J. ;
Srinivasan, Ashok ;
Wang, Ying ;
Pogue-Geile, Katherine L. ;
Lucas, Peter C. ;
Jacobs, Samuel A. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) :2601-+
[2]  
[Anonymous], 2011, J Clin Oncol
[3]  
Christianson TA, 1998, CANCER RES, V58, P5123
[4]   High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance) [J].
Chumsri, Saranya ;
Sperinde, Jeff ;
Liu, Heshan ;
Gligorov, Joseph ;
Spano, Jean-Philippe ;
Antoine, Martine ;
Aspitia, Alvaro Moreno ;
Tan, Winston ;
Winslow, John ;
Petropoulos, Christos J. ;
Chenna, Ahmed ;
Bates, Michael ;
Weidler, Jodi Marie ;
Huang, Weidong ;
Dueck, Amylou ;
Perez, Edith A. .
CLINICAL CANCER RESEARCH, 2018, 24 (13) :3053-3058
[5]   Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab [J].
Duchnowska, Renata ;
Sperinde, Jeff ;
Czartoryska-Arlukowicz, Bogumila ;
Mysliwiec, Paulina ;
Winslow, John ;
Radecka, Barbara ;
Petropoulos, Christos ;
Demlova, Regina ;
Orlikowska, Marlena ;
Kowalczyk, Anna ;
Lang, Istvan ;
Ziolkowska, Barbara ;
Debska-Szmich, Sylwia ;
Merdalska, Monika ;
Grela-Wojewoda, Aleksandra ;
Zawrocki, Anton ;
Biernat, Wojciech ;
Huang, Weidong ;
Jassem, Jacek .
ONCOTARGET, 2017, 8 (61) :104149-104159
[6]   Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff [J].
Duchnowska, Renata ;
Sperinde, Jeff ;
Chenna, Ahmed ;
Haddad, Mojgan ;
Paquet, Agnes ;
Lie, Yolanda ;
Weidler, Jodi M. ;
Huang, Weidong ;
Winslow, John ;
Jankowski, Tomasz ;
Czartoryska-Arlukowicz, Bogumila ;
Wysocki, Piotr J. ;
Foszczynska-Kloda, Malgorzata ;
Radecka, Barbara ;
Litwiniuk, Maria M. ;
Zok, Jolanta ;
Wisniewski, Michal ;
Zuziak, Dorota ;
Biernat, Wojciech ;
Jassem, Jacek .
CLINICAL CANCER RESEARCH, 2014, 20 (10) :2805-2813
[7]   Breast Cancer, Version 3.2022 [J].
Gradishar, William J. ;
Moran, Meena S. ;
Abraham, Jame ;
Aft, Rebecca ;
Agnese, Doreen ;
Allison, Kimberly H. ;
Anderson, Bethany ;
Burstein, Harold J. ;
Chew, Helen ;
Dang, Chau ;
Elias, Anthony D. ;
Giordano, Sharon H. ;
Goetz, Matthew P. ;
Goldstein, Lori J. ;
Hurvitz, Sara A. ;
Isakoff, Steven J. ;
Jankowitz, Rachel C. ;
Javid, Sara H. ;
Krishnamurthy, Jairam ;
Leitch, Marilyn ;
Lyons, Janice ;
Mortimer, Joanne ;
Patel, Sameer A. ;
Pierce, Lori J. ;
Rosenberger, Laura H. ;
Rugo, Hope S. ;
Sitapati, Amy ;
Smith, Karen Lisa ;
Smith, Mary Lou ;
Soliman, Hatem ;
Stringer-Reasor, Erica M. ;
Telli, Melinda L. ;
Ward, John H. ;
Wisinski, Kari B. ;
Young, Jessica S. ;
Burns, Jennifer ;
Kumar, Rashmi .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (06) :691-722
[8]   Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy [J].
Lluis Parra-Palau, Josep ;
Morancho, Beatriz ;
Peg, Vicente ;
Escorihuela, Marta ;
Scaltriti, Maurizio ;
Vicario, Rocio ;
Zacarias-Fluck, Mariano ;
Pedersen, Kim ;
Pandiella, Atanasio ;
Nuciforo, Paolo ;
Serra, Violeta ;
Cortes, Javier ;
Baselga, Jose ;
Perou, Charles M. ;
Prat, Aleix ;
Rubio, Isabel T. ;
Arribas, Joaquin .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (11)
[9]   A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers [J].
Lluis Parra-Palau, Josep ;
Pedersen, Kim ;
Peg, Vicente ;
Scaltriti, Maurizio ;
Davide Angelini, Pier ;
Escorihuela, Marta ;
Mancilla, Sandra ;
Sanchez Pla, Alexandre ;
Ramon y Cajal, Santiago ;
Baselga, Jose ;
Arribas, Joaquin .
CANCER RESEARCH, 2010, 70 (21) :8537-8546
[10]   Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients [J].
Maria, Alaa Mohamed ;
El-Shebiney, Mohamed ;
El-Saka, Ayman Mohamed ;
Zamzam, Yomna .
JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (02) :49-55